Publications in collaboration with researchers from Essen University Hospital (24)

2025

  1. Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer

    Nature Medicine, Vol. 31, Núm. 8, pp. 2755-2767

  2. Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary

    Future Oncology, Vol. 21, Núm. 9, pp. 1033-1044

  3. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

    New England Journal of Medicine, Vol. 393, Núm. 4, pp. 349-361

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

2023

  1. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  2. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

2022

  1. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645

  2. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients with Cancer: A Narrative Review

    JAMA Oncology, Vol. 8, Núm. 12, pp. 1830-1839

2019

  1. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

    Lung Cancer, Vol. 133, pp. 10-19

  2. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

    Journal of Cancer Research and Clinical Oncology, Vol. 145, Núm. 6, pp. 1569-1579

  3. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer

    Lung Cancer, Vol. 132, pp. 126-131

2018

  1. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. e465-e479

2017

  1. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)

    Journal of Clinical Oncology

2015

  1. 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer

    Annals of Oncology, Vol. 26, Núm. 8, pp. 1573-1588

  2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    New England Journal of Medicine, Vol. 373, Núm. 2, pp. 123-135

2014

  1. 2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1475-1484

  2. 2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1462-1474

  3. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

    Clinical Cancer Research, Vol. 20, Núm. 16, pp. 4251-4261

  4. Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

    Annals of Oncology, Vol. 25, Núm. 9, pp. 1681-1690

2013

  1. Epidermal growth factor receptor inhibition in lung cancer: Status 2012

    Journal of Thoracic Oncology, Vol. 8, Núm. 3, pp. 373-384